Supplementary Figure 1 - Engineered mesoporous silica reduces long-term blood glucose and HbA1c, and improve metabolic parameters in prediabetics
Supplementary Figure 1. Effect of SiPore15® treatment during the entire 24-week clinical trial period: 12 weeks of treatment and 12 weeks of follow-up. Changes in the (a) HbA1c level, (b) body weight, (c) BMI, (d) total cholesterol level, (e) LDL cholesterol level, (f) SAD, (g) insulin level, (h) HOMA-IR were measured during the 12-week treatment period and continued to be measured 12 weeks after treatment had finished. The data were analyzed using the Wilcoxon signed rank test where the comparison was between the specific time point (week 6, 12, 18, 24) and the baseline. P values less than 0.05 were considered statistically significant and are shown above. All data are presented as mean + SEM (n=38 for All-participants group, n=27 at baseline and at week 6 and n=9 at week 12, 18, 24 for Conformant-batch group).